Roivant Sciences Ltd. financial data

Symbol
ROIV on Nasdaq
Industry
Pharmaceutical Preparations
Location
Clarendon House, 2 Church Street, Hamilton Hm11, Bermuda
State of incorporation
Bermuda
Fiscal year end
March 31
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.13K % +214%
Quick Ratio 8 %
Debt-to-equity 15.4 % -78.9%
Return On Equity 93.5 %
Return On Assets 82 %
Operating Margin 2.78K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 739M shares -3.66%
Common Stock, Shares, Outstanding 739M shares -3.66%
Entity Public Float 8B USD +1697%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 736M shares -3.09%
Weighted Average Number of Shares Outstanding, Diluted 782M shares +2.94%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 158M USD +101%
Research and Development Expense 510M USD -0.92%
General and Administrative Expense 841M USD +195%
Operating Income (Loss) 4.4B USD +56.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 4.65B USD
Income Tax Expense (Benefit) 33.1M USD +1026%
Net Income (Loss) Attributable to Parent 4.74B USD
Earnings Per Share, Basic 6.06 USD/shares
Earnings Per Share, Diluted 5.73 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.68B USD +296%
Inventory, Net 34M USD +705%
Other Assets, Current 323M USD +154%
Assets, Current 6B USD +284%
Property, Plant and Equipment, Net 17.8M USD -50.8%
Operating Lease, Right-of-Use Asset 45.3M USD -12.2%
Intangible Assets, Net (Excluding Goodwill) 136M USD -6.23%
Other Assets, Noncurrent 32.8M USD -29.2%
Assets 6.5B USD +204%
Accounts Payable, Current 27.7M USD -44.6%
Employee-related Liabilities, Current 37.8M USD +89.9%
Accrued Liabilities, Current 138M USD +15.9%
Liabilities, Current 215M USD -12.2%
Operating Lease, Liability, Noncurrent 45.9M USD -11.5%
Other Liabilities, Noncurrent 1.66M USD -90.2%
Liabilities 601M USD -25.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -17.9M USD -172%
Retained Earnings (Accumulated Deficit) 671M USD
Stockholders' Equity Attributable to Parent 5.44B USD +497%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 5.9B USD +342%
Liabilities and Equity 6.5B USD +204%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -193M USD +22.8%
Net Cash Provided by (Used in) Financing Activities -661M USD -8935%
Net Cash Provided by (Used in) Investing Activities -965K USD -1019%
Common Stock, Shares Authorized 7B shares 0%
Common Stock, Shares, Issued 739M shares -3.66%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -857M USD -254%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.69B USD +293%
Deferred Tax Assets, Valuation Allowance 767M USD +13.7%
Deferred Tax Assets, Gross 785M USD +12.6%
Operating Lease, Liability 57.2M USD -12.3%
Payments to Acquire Property, Plant, and Equipment 965K USD +139%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 4.72B USD
Lessee, Operating Lease, Liability, to be Paid 75.4M USD -22.6%
Operating Lease, Liability, Current 9.49M USD -16.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 9.66M USD -15.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.7M USD -21.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure -12.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.85M USD -13.9%
Deferred Tax Assets, Operating Loss Carryforwards 519M USD +22.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.87M USD -6.55%
Additional Paid in Capital 4.78B USD -4.02%
Depreciation, Depletion and Amortization 4.88M USD -16.4%
Share-based Payment Arrangement, Expense 565M USD +565%
Interest Expense 39.3M USD +14.6%